Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio. Credit: Crinetics Pharmaceuticals Subscribe now Already have an account? Sign in.
